Truist Financial Issues Positive Forecast for Pediatrix Medical Group (NYSE:MD) Stock Price

Pediatrix Medical Group (NYSE:MD) had its price objective raised by research analysts at Truist Financial from $13.00 to $16.00 in a report released on Monday, Benzinga reports. The brokerage presently has a “hold” rating on the stock. Truist Financial’s target price suggests a potential upside of 7.10% from the company’s current price.

MD has been the topic of several other reports. Mizuho raised their target price on Pediatrix Medical Group from $13.00 to $15.00 and gave the stock a “neutral” rating in a research note on Monday. UBS Group raised their target price on Pediatrix Medical Group from $9.00 to $10.50 and gave the stock a “neutral” rating in a research note on Friday, August 9th. StockNews.com raised Pediatrix Medical Group from a “sell” rating to a “hold” rating in a research note on Wednesday, August 7th. Finally, Jefferies Financial Group upgraded shares of Pediatrix Medical Group from a “hold” rating to a “buy” rating and raised their price objective for the stock from $8.00 to $14.00 in a report on Thursday, September 26th. Five investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $12.70.

Pediatrix Medical Group Price Performance

MD traded down $0.27 during trading on Monday, reaching $14.94. The stock had a trading volume of 202,923 shares, compared to its average volume of 868,271. The stock has a market cap of $1.28 billion, a PE ratio of -4.88, a PEG ratio of 1.91 and a beta of 1.55. The company has a debt-to-equity ratio of 0.87, a quick ratio of 1.38 and a current ratio of 1.38. Pediatrix Medical Group has a one year low of $6.62 and a one year high of $15.42. The business has a 50-day moving average of $11.62 and a 200-day moving average of $9.40.

Pediatrix Medical Group (NYSE:MD) last announced its quarterly earnings data on Friday, November 1st. The company reported $0.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.37 by $0.07. Pediatrix Medical Group had a positive return on equity of 10.59% and a negative net margin of 12.58%. The firm had revenue of $511.20 million for the quarter, compared to analysts’ expectations of $498.87 million. During the same period last year, the firm earned $0.29 earnings per share. The company’s revenue for the quarter was up .9% compared to the same quarter last year. As a group, equities research analysts anticipate that Pediatrix Medical Group will post 1.19 EPS for the current fiscal year.

Insider Activity

In related news, Director Laura A. Linynsky sold 7,000 shares of Pediatrix Medical Group stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $11.16, for a total transaction of $78,120.00. Following the transaction, the director now directly owns 30,805 shares in the company, valued at approximately $343,783.80. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, CEO James D. Swift sold 11,100 shares of the stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $10.79, for a total transaction of $119,769.00. Following the completion of the sale, the chief executive officer now owns 170,001 shares in the company, valued at approximately $1,834,310.79. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Laura A. Linynsky sold 7,000 shares of the stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $11.16, for a total value of $78,120.00. Following the sale, the director now owns 30,805 shares of the company’s stock, valued at $343,783.80. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 68,100 shares of company stock valued at $701,889 in the last 90 days. Company insiders own 2.00% of the company’s stock.

Hedge Funds Weigh In On Pediatrix Medical Group

Several institutional investors have recently added to or reduced their stakes in MD. Vanguard Group Inc. lifted its stake in shares of Pediatrix Medical Group by 1.6% in the 1st quarter. Vanguard Group Inc. now owns 10,557,572 shares of the company’s stock valued at $105,892,000 after purchasing an additional 164,333 shares during the last quarter. Rubric Capital Management LP lifted its stake in shares of Pediatrix Medical Group by 797.0% during the 2nd quarter. Rubric Capital Management LP now owns 8,150,000 shares of the company’s stock worth $61,532,000 after acquiring an additional 7,241,400 shares during the last quarter. Boston Partners lifted its stake in shares of Pediatrix Medical Group by 34.0% during the 1st quarter. Boston Partners now owns 1,786,434 shares of the company’s stock worth $17,702,000 after acquiring an additional 453,254 shares during the last quarter. Dana Investment Advisors Inc. lifted its stake in shares of Pediatrix Medical Group by 80.3% during the 2nd quarter. Dana Investment Advisors Inc. now owns 1,023,136 shares of the company’s stock worth $7,725,000 after acquiring an additional 455,785 shares during the last quarter. Finally, Brandes Investment Partners LP raised its position in Pediatrix Medical Group by 12.8% during the 2nd quarter. Brandes Investment Partners LP now owns 735,068 shares of the company’s stock valued at $5,438,000 after purchasing an additional 83,588 shares in the last quarter. Hedge funds and other institutional investors own 97.71% of the company’s stock.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.